Dana T. Aftab

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · The Lancet Oncology · 2016 · 927 citations · Full text

Urology, Genitourinary Cancer, Kidney Research +8

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

Barbara Sennino, Toshina Ishiguro‐Oonuma, Ying Wei et al. · Cancer Discovery · 2012 · 414 citations · Full text

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

Weon‐Kyoo You, Barbara Sennino, Casey W. Williamson et al. · Cancer Research · 2011 · 258 citations · Full text

Angiogenesis Inhibitors, Immunology, Block Vegf Receptor +16

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

Glenn Heller, Robert McCormack, Thian Kheoh et al. · Journal of Clinical Oncology · 2017 · 229 citations · Full text

Ctc Nonzero, Cancer Management, Ctc Count +17

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

Anna Kwilas, Andressa Ardiani, Renee N. Donahue et al. · Journal of Translational Medicine · 2014 · 185 citations · Full text